Drug delivery, Financing

CeQur in $27 million series B financing round

Posted on 10 September 2013

Tags: , ,

CeQur SA announced the closing of a $27 million dollar Series B financing.

The series B financing round was led by two new private investors with the participation of all current shareholders, and will support manufacturing scale up for the CeQur PaQ simple insulin delivery device, which received CE Mark approval in November 2012.

Proceeds from this series B financing round will also be used to fund activities related to United States regulatory approval.

In a study involving people with type 2 diabetes completed last year, PaQ safely and effectively delivered patients' insulin requirements with a high level of patient satisfaction and acceptance, and demonstrated ability to reduce known barriers to insulin therapy and a trend towards improving patients' glycemic control.

Related

View: Current Partnering’s Financing Scorecard – view top life science financing deals by value

Report: Drug Delivery Partnering Terms and Agreements

Report: Diabetes Partnering

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply